28 Analysts Have This To Say About Regeneron Pharmaceuticals
28 Analysts Have This To Say About Regeneron Pharmaceuticals
28 位分析师对再生元制药公司的看法
The standing of Regeneron Pharmaceuticals...Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
再生元制药公司（纳斯达克:REGN）在上个季度接受了28名分析师的分析，显示出从看好到看淡的不同观点。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他们最近的评级概况，突出了过去30天内情绪的变化，并将其与之前的月份进行了比较。
Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $1156.14, accompanied by a high estimate of $1300.00 and a low estimate of $895.00. Experiencing a 3.64% decline, the current average is now lower than the previous average price target of $1199.85.
分析师最近评价了再生元制药公司，并提供了12个月的价格目标。平均目标为1156.14美元，最高估计为1300.00美元，最低估计为895.00美元。经历了3.64%的下降，当前平均值目前低于之前的平均价格目标1199.85美元。
Decoding Analyst Ratings: A Detailed Look
Decoding Analyst Ratings: A Detailed Look
The standing of Regeneron Pharmaceuticals...
通过对最近...
登录免费看全文
登录/注册
资讯热榜
更新时间